BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-137@catalystbrief.girapphe.com
DTSTAMP:20261117T181604Z
LAST-MODIFIED:20261117T181604Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Boehringer Ingelheim — Nerandomilast [Apr 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Test Whether Nerandomila
 st Helps People With Lung Fibrosis Related to Rheumatic Diseases.\nSource:
  https://clinicaltrials.gov/study/NCT06806592\nhttps://catalystbrief.girap
 phe.com/e/137?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/137?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
